University of Hertfordshire

Standard

Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome. / Bor, Wilbert; Gorog, Diana.

In: Journal of Clinical Medicine, Vol. 9, No. 7, 01.07.2020.

Research output: Contribution to journalArticle

Harvard

APA

Vancouver

Author

Bibtex

@article{3e5a848bd4e44ed3b1a7df752fc146f8,
title = "Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome",
abstract = "Abstract: Acute coronary syndrome and atrial fibrillation are both common, and can occur in the same patient. Combination therapy with dual antiplatelet therapy and oral anticoagulation increases risk of bleeding. Where the two conditions co-exist, careful consideration is needed to determine the optimal antithrombotic treatment to reduce the risks of future ischaemic events associated with both conditions. Choices can be made in intraprocedural anticoagulation, type and dosing of oral anticoagulant, duration of combination therapy, and selection of P2Y12 inhibitor including genetic testing. This review article provides an overview of the available evidence to support clinicians in finding the delicate balance between antithrombotic efficacy and bleeding risk in patients with acute coronary syndrome and atrial fibrillation.",
author = "Wilbert Bor and Diana Gorog",
note = "{\textcopyright} 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).",
year = "2020",
month = jul,
day = "1",
doi = "10.3390/jcm9072020",
language = "English",
volume = "9",
journal = "Journal of Clinical Medicine",
issn = "2077-0383",
number = "7",

}

RIS

TY - JOUR

T1 - Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome

AU - Bor, Wilbert

AU - Gorog, Diana

N1 - © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PY - 2020/7/1

Y1 - 2020/7/1

N2 - Abstract: Acute coronary syndrome and atrial fibrillation are both common, and can occur in the same patient. Combination therapy with dual antiplatelet therapy and oral anticoagulation increases risk of bleeding. Where the two conditions co-exist, careful consideration is needed to determine the optimal antithrombotic treatment to reduce the risks of future ischaemic events associated with both conditions. Choices can be made in intraprocedural anticoagulation, type and dosing of oral anticoagulant, duration of combination therapy, and selection of P2Y12 inhibitor including genetic testing. This review article provides an overview of the available evidence to support clinicians in finding the delicate balance between antithrombotic efficacy and bleeding risk in patients with acute coronary syndrome and atrial fibrillation.

AB - Abstract: Acute coronary syndrome and atrial fibrillation are both common, and can occur in the same patient. Combination therapy with dual antiplatelet therapy and oral anticoagulation increases risk of bleeding. Where the two conditions co-exist, careful consideration is needed to determine the optimal antithrombotic treatment to reduce the risks of future ischaemic events associated with both conditions. Choices can be made in intraprocedural anticoagulation, type and dosing of oral anticoagulant, duration of combination therapy, and selection of P2Y12 inhibitor including genetic testing. This review article provides an overview of the available evidence to support clinicians in finding the delicate balance between antithrombotic efficacy and bleeding risk in patients with acute coronary syndrome and atrial fibrillation.

U2 - 10.3390/jcm9072020

DO - 10.3390/jcm9072020

M3 - Article

VL - 9

JO - Journal of Clinical Medicine

JF - Journal of Clinical Medicine

SN - 2077-0383

IS - 7

ER -